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Summary 
We have previously produced lines of rats transgenic for HLA-B27 and human 32-microglobulin 
(h32m) that develop  a progressive  inflammatory disease sharing many clinical  and histologic 
features with the B27-associated human spondyloarthropathies, including gut and male genital 
inflammation, arthritis, and psoriasiform skin lesions. Other transgenic lines that express lower 
levels of B27 and h/~zrn remain healthy.  To investigate  the cellular basis for the multisystem 
inflammatory disease in these rats, we transferred lymphoid cell populations from disease-prone 
transgenic lines to irradiated disease-resistant transgenic and nontransgenic recipients. In recipients 
of cells from two different disease-prone lines, successful transfer required engraftment of bone 
marrow cells. Transfer of disease with fetal liver cells suggested that neither mature effector cells 
nor active disease in the donors was necessary for induction of disease in the recipients. Remission 
of the spontaneous disease in irradiated transgenic rats was induced by engraftment of nontransgenic 
bone marrow. These results suggest that the expression of HLA-B27 in bone marrow-derived 
cells alone is sufficient for the development of B27-associated disease, and that disease transfer 
requires  engraftment of a bone marrow precursor cell for which mature cells in spleen or in 
lymph node cannot substitute. 
S 
everal human diseases show association and genetic linkage 
with class I or II alleles of the HLA complex (1). Among 
the most striking of these associations is that of the class I 
allele HLA-B27 with the disorders termed spondyloarthropa- 
thies,  in which there is inflammatory involvement of axial 
and peripheral joints, gastrointestinal and genitourinary tracts, 
skin, eye, and heart (summarized in reference 2). For most 
HLA-associated disorders, it has not been determined whether 
the associated alleles participate directly in disease pathogen- 
esis. However, for the HLA-B27-associated spondyloarthropa- 
thies, the development of similar disease in transgenic rats 
expressing HLA-B27 has provided strong evidence for direct 
participation by the B27 molecule. Rats of two transgenic 
lines, 21-4H and 33-3, each hemizygous for a transgene locus 
bearing  genes  encoding  HLA-B*2705  and  human  82- 
microglobulin (hB2m), 1 uniformly develop  a  progressive 
inflammatory disease (2, 3). The major features of this dis- 
ease include chronic diarrhea resulting from gastrointestinal 
inflammation, peripheral and axial arthritis, psoriasiform skin 
and nail changes, and male genital inflammation. In a third 
1  Abbreviations used in this ~tn'r: BM, bone marrow; FL, fetal liver; hBzm, 
human 32-microglobulin. 
line, 21-3, similar disease develops in rats that are homozy- 
gous for the transgene locus, whereas the hemizygotes re- 
main healthy. Rats that are either hemi- or homozygous for 
the transgene loci of the 21-4L and 25-6 lines, which bear 
fewer copies of the transgenes than the 21-4H, 33-3 and 21-3 
lines, have remained uniformly healthy (3). All five lines bear 
the  same  genomic  HLA-B*2705  and  h~2m  constructs, 
differing with respect to the transgenes only in the numbers 
of copies and levels of expression  (2,  3). 
Because the histologic appearance of the lesions suggested 
strongly that the disease in rats is immune mediated, and 
because an immune pathogenesis is also suspected in most 
of the B27-associated disease manifestations in humans (4, 
5), we sought to identify cells of the immune system that 
could transfer the disease induced by the B27 transgene. Here 
we report the results  of these cell transfer  experiments. 
Materials  and Methods 
Animals.  The transgenic rat lines 21-4L, bearing 6 copies each 
of the HLA-B*2705 and hB2m genes; 21-4H, bearing 150 copies 
of the B'2705 gene and 90 copies of the hB2m gene; and 33-3, 
bearing 55 copies of the B'2705 gene and 66 copies of the hB2m 
gene, were  produced and maintained  in our animal colony as previ- 
ously described  (2). Nontransgenic LEW and F344 rats were pur- 
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1992, after many of the experiments involving the 21-4H and 21- 
4L lines had been carried out, we became aware that Charles River, 
Inc., had provided us with LEW breeding stock in 1991 that was 
contaminated with genes from an outbred line. Typing by hemag- 
glutination for three RBC alloantigenic systems (RT2, RT3, and 
RTS) (6, 7) and for MHC haplotype (RT1) indicated that some 
rats of the 21-4L line carried a non-LEW RT2 allele, but all were 
homozygous for the expected LEW alleles at RTI, RT3, and RTS. 
Some rats of the 21-4H line were found to carry a non-LEW RT/ 
haplotype (RT/'), but all were homozygous for the expected LEW 
alleles at RT2, RT3, and RTS. Rats of the 33-3 line showed only 
F344 alleles at four out of four unlinked loci typed serologically, 
and also at 10 out of 10 unlinked loci identified by microsatellite 
DNA polymorphisms, as described (8). The 33-3 line was there- 
fore likely to be authentically inbred on the F344 background. 
Celt Suspensions.  Single cell suspensions were prepared from bone 
marrow (BM), spleen, peripheral or mesenteric LN, or blood, as 
described (9). Fetuses from time-mated pregnant females were har- 
vested at various gestational points (presence of  vaginal sperm taken 
as day 0). Single cell suspensions of fetal liver (FL) cells were made 
by disruption of minced fetal liver with a Pasteur  pipette in 0.5 
ml  Dulbecco's  PBS  and  filtration  through  nylon  mesh  before 
counting and injection. The HLA-B27 transgene status of the fe- 
tuses was determined by dot-blot hybridization of genomic DNA, 
as described  (2). 
Cell Transfers.  Recipients were either sublethally (300, 500, or 
750 rad) or lethally (950, 1,050, or 1,350 tad) irradiated at 70 rad/min 
from a 137Cs source (Gammacell 40;  Atomic Energy of Canada, 
Ltd., Kanala, Ont., Canada), 2-36 h before reconstitution. All cell 
suspensions were injected intravenously through the external jugular 
vein under ether anesthesia.  Single cell suspensions  prepared from 
individual FL were injected into individual recipients.  Lethally ir- 
radiated nontransgenic F344 recipients  of 33-3 LN cells also re- 
ceived a rescuing inoculum of 3  x  107 FL cells from day 16 non- 
transgenic syngeneic fetuses. 
Clinical Evaluation.  Recipients were monitored five times per 
week for chronic diarrhea, arthritis, and skin changes developing 
after or persisting beyond the first month after irradiation. The 
severity of diarrhea, arthritis, and skin changes was given a daily 
severity score of 0-4 each. The average daily total of these scores 
was calculated each week, with a maximum of 12, and the average 
of these weekly scores for each rat for the first 3 mo after the onset 
of disease was used as an index of disease severity. In all passive 
transfer experiments, control rats were observed past the time of 
latest  onset of disease in affected rats.  Fatal cachexia beyond the 
first month after irradiation was considered a consequence of the 
inflammatory disease manifestation, since in preliminary studies 
the radiation doses termed lethal (950-1,350 tad) were uniformly 
fatal within 3 wk in unreconstituted rats. 
Flow Cytometry Analysis.  Single and two-color flow cytometry 
were carried out as described (3), with some modifications. The 
following mouse mAb and their specificities were used, references 
for which are cited in (3): B1.23.2,  IgG2a, monomorphic HLA-B 
and -C; R73, IgG1, rat TCR-o#3 C region;W3/25, IgG1, rat CD4; 
OX8 IgG1, rat CD8~ chain; OX33, IgG1, B cell-specific epitope 
of rat CD45; and OX19, IgG1, rat CD5. The mAb 3.2.3, IgG1, 
recognizing NKP-P1, a rat NK cell-specific  surface protein (10), 
and OX-42, IgG2a, recognizing rat C3b receptor (11) were also 
used. Irrelevant IgG2a and IgG1 mAb served as negative controls. 
All procedures were carried out at 4~  in DPBS containing 4% 
FCS and 0.05% sodium azide (staining  buffer). For single color 
direct fluorescence, cells were preincubated 20 min in 50 #1 staining 
buffer containing 20% rat serum before addition of 50 #1 staining 
buffer containing directly conjugated FITC-B1.23.2 at twice the 
saturating concentration for a 30-min incubation. For two-color 
staining, cells were incubated with mAb in the following sequence, 
with two washes after each incubation: relevant IgG1 mAb, FITC- 
conjugated rat anti-mouse IgG1 (Zymed Laboratories,  Inc., S. San 
Francisco, CA), biotinylated B1.23.2,  PE-conjugated streptavidin 
(Pierce, Rockford, IL). For single color indirect fluorescence, cells 
were incubated with biotinylated B1.23.2 followed by PE-conjugated 
streptavidin. After two washes and filtration through nylon mesh, 
flow cytometry was carried out as described  (3). 
Histopathology and Immunocytochemistry.  These were carried out 
as described  (2, 3).  In addition to the mAb listed above, HC-10, 
mouse IgG2b, specific for HLA-B H chain (12), was also used for 
immunocytochemistry. 
Results 
Transfer of Disease to Transgenic 21-4L Rats.  We initially 
assumed that the presence of HLA-B27 on nonhematopoietic 
cells within  the target  tissues  of the disease,  as well as on 
hematopoietic cells, might be important for disease expres- 
sion. Therefore, rats of the disease-resistant B27 transgenic 
21-4L line were used as recipients for cell suspensions from 
sick  donor rats  of the  21-4H  disease-prone line (Table 1). 
Transfer of BM cells,  alone or mixed with  spleen cells,  to 
sublethally irradiated (500-750 rad) recipients was associated 
in  11  of the  18 cases with persistent  diarrhea  starting  2-5 
wk  after  transfer  (group  1A,  i.e.,  group  A,  Table  1).  10 
recipients also later developed skin or nail changes resembling 
the spontaneous disease,  and one recipient developed arthritis. 
In this first group of recipients, the number of BM cells in- 
jected ranged from 0.75  to 9  x  10  s per recipient with  no 
clear correlation between cell dose and the incidence or severity 
of disease in the recipients. In most subsequent experiments, 
a  standard  dose of 10  s BM cells was  used.  After lethal ir- 
radiation (1,050 rad) and transplantation  of 21-4H BM,  12 
out of 12 21-4L recipients developed disease (group 1E) that 
was  earlier in onset and more severe than that  seen in the 
sublethally irradiated 21-4L recipients. These results indicated 
a  significant influence of the radiation dose on the efficacy 
of disease transfer. 
Histologic study of four of the sick recipients after 4-18 
wk of disease showed mucosal  inflammation  diffusely dis- 
tributed throughout the colon in all four rats and more fo- 
cally distributed in the small intestine and stomach. Lesions 
were similar  to those of the spontaneous  disease (2),  con- 
sisting  mainly  of mononuclear  infiltration  of the  lamina 
propria,  crypt  epithelial  hyperplasia,  and  loss  of mucin- 
containing cells (Fig.  1 A).  In the more severe cases,  crypt 
abscesses were present. No vasculitic lesions were seen. Skin 
(Fig. 2 A) and nail changes similar to the findings in the spon- 
taneous  disease were also  present,  consisting  of epidermal 
hyperplasia and hyperkeratosis with dermal inflammation and 
perifolliculitis. Glossitis with histologic characteristics similar 
to  that  seen in  the  skin  was  present  in  three of the four 
recipients examined. This finding is also present in the spon- 
taneous disease (our unpublished  results).  No liver abnor- 
malities were seen in  any of the four rats  examined. 
1608  Bone Marrow Transfer of HLA-B27-associated Disease in Rats Table  1.  Passive Transfer of B27-associated Disease to Irradiated 21-4L  Rats 
Cells  injected  With  Skin  Death  Wk of onset  Severity index 
Group  Donor cells  x l0 -s (range)  Total  disease  Diarrhea  Arthritis  lesions  (1-4 mo)  Mean  +  SEM  Mean  _+  SEM 
Sublethal  irradiation  (500-750 rad) 
A  21-4H BM  0.75-9  18  12  11  1  10  0  7  _+  3  1.7  +  0.3 
(+SP)*  (0.6-3)*  (4)  (3)  (3)  (1)  (2)  (0)  (3  +_  1)  (3.2  +  0.5) 
B  21-4H SP  2-4  8  1  0  0  1  0  22  1 
C  21-4H LN  3-5  7  1  0  0  1  0  31  1.1 
D  21-4L BM  5-9  7  0  0  0  0  0  -  - 
( + SP)  (2)  (2)  (0)  (0)  (0)  (0)  (0) 
Lethal irradiation  (950-1,050 rads) 
E  21-4H BM  1  12  12  12  0  12  9 
F  21-4H SP  1  6  6  6  1  5  0 
G  21-4L BM  1  6  0  0  0  0  0 
H  Ntg LEW BM  1  10  0  0  0  0  0 
+ SP + LN  (1.5) 
4  +  0  2.2  _+  0.2 
7  +  2  0.7  _+  0.1 
5-23-wk-old irradiated B27/hBzm transgenic rats of the disease-resistant 21-4L line received i.v. BM, spleen (SP), or LN cells from sick donor rats 
of the B27/h/32m transgenic disease-prone 21-4H line, from 21-4L donor rats or from nontransgenic (Ntg) donor rats. Recipients were monitored 
for clinical manifestations developing  after or persisting beyond the first month after irradiation. Severity  index was calculated from rats showing disease. 
" Notations in parentheses refer to recipients of BM cells that  received SP cells along with BM cells. 
* Number of SP and/or  LN cells injected along with BM cells in recipients of mixed cells. 
In contrast with these results observed with BM, and par- 
ticnlarly in contrast with the severe disease seen in recipients 
of BM plus spleen cells (group 1A), transfer of spleen or LN 
cells alone to sublethally irradiated recipients had an almost 
negligible clinical effect. Only one of eight spleen cell recipients 
and one of seven LN cell  recipients  developed any sign of 
disease, and this was confirmed to alopecia beginning 22 and 
31 wk, respectively, after irradiation and cell transfer (groups 
1B and C). One of these two recipients was examined histo- 
logically and showed dermal perifoUiculitis but no epidermal 
hyperplasia or inflammation. The colonic mucosa was normal. 
This result suggested that engraftment by BM stem cells may 
be required for transfer of disease. Since spleen contains a small 
population of hematopoietic  stem  cells (13),  if these could 
be successfully engrafted,  it might be expected that disease 
would ensue.  This prediction was borne out by the finding 
Figure  1.  Histopathology of chronic colitis induced in disease-resistant 
rats after transfer of BM cells from disease-prone rats. (A) Colon of a 21- 
4L male recipient of 21-4H BM cells 18 wk after irradiation (750 rad) 
and cell transfer (group 1A). The section shows  chronic  colitis  with hyper- 
plasia of epithelial ceUs, loss of mucin-containing  cells, and increased depth 
of crypts. Marked infiltration by mononuclear  cells is present throughout 
the lamina propria. (/3) Colon of a nontransgenic LEW male recipient 
of 21-4L  BM cells 10 wk after irradiation (1,050 tad) and cell transfer (group 
2G). The histologic appearance is normal, (C) Colon of a nontransgenic 
female LEW recipient of 21-4H FL cells 5 wk after irradiation (1,050 tad) 
and cell transfer (group 2E). Lesions are present similar to those in A. 
(D) Colon of a 43-wk-old 33-3 female recipient of nontransgenic F344 
BM ceUs 18 wk after irradiation (950 tad) and cell transfer showing normal 
crypt size and normal cellularity in the lamina propria. The presence of 
submucosal fibrosis appears to be a sequela of the healing process (A-D, 
x 130). 
1609  Breban  et al. Figure 2.  Histopathologyoftheskinandjointindisease- 
resistant rats after transfer of  BM cells  from disease-prone  rats. 
(A) Tail skin of a 21-4L male recipient of 21-4H BM cells 
(same rat as in Fig. 1 A), showing psoriasiform epidermal 
hytx~hsia and inflammatory infiltration of the dermal papillae 
and epidermis. (B) Tail  skin of a nontransgenic  female F344 
recipient of 33-3 BM cells. Lesions are present similar to those 
in A. (C) Tail skin of a nontransgenic  LEW female recipient 
of 21-4L BM cells 8 wk after irradiation (1,050 rads) and cell 
transfer (group 2G). The histologic appearance  is normal. (D) 
Arthritic  joint of a nontransgenic  LEW female recipients of 
21-4H BM cells 4 wk after irradiation  (1,050 rad) and cell 
transfer (group 2D), showing inflammatory infiltration and 
hyperplasia of the synovial tissue and pannus formation with 
erosion of the cartilage and subchondral bone (A-D,  x 102). 
that six of six lethally irradiated 21-4L recipients of 21-4H 
spleen cells developed overt disease (group 1F). Disease in 
this group was milder and later in onset than that of com- 
parable recipients of BM, as might be expected if disease was 
dependent upon stem cell engraftment and if the number of 
transferred  stem cells was lower. Sublethally and lethally ir- 
radiated 21-4L recipients of control 21-4L or nontransgenic 
LEW cells remained healthy throughout the 13-60-wk period 
of observation (groups 1D, G,  and H). Flow cytometry of 
spleen and PBM cells at 7-35 wk after transfer showed a popu- 
lation with high B27 surface expression in recipients that de- 
veloped  disease  (Fig.  3  C,  fluorescence  intensity  >103), 
similar  to a population present in the 21-4H donors (Fig. 
3 A), whereas both the 21-4L recipients of 21-4L BM cells 
(group 1D, data not shown) and the 21-4L recipients that 
remained healthy after receiving 21-4H BM (group 1A, Fig. 
3 D) showed a typical 21-4L pattern of B27 surface expres- 
sion (Fig.  3 B). 
Transfer of Disease to Nontransgenic Recipients.  The results 
obtained with the 21-4L recipients suggested that the recipients 
developing disease were largely repopulated by donor-derived 
hematopoietic cells after irradiation.  However, the role of B27 
expression in recipient cells not derived from BM remained 
undefined. Immunohistochemistry  of the lesions in animals 
exhibiting the spontaneous disease had consistently shown 
B27 expression predominantly restricted to lymphoid cells, 
with negligible staining for B27 on gut epithelial cells (3). 
This suggested that disease induction might depend on B27 
expression in lymphoid cells alone. Experiments were there- 
fore performed in which 21-4H, 21-4L, 33-3,  or nontrans- 
genic F344 BM cells were transferred  to lethally irradiated, 
sex- and strain-matched, nontransgenic LEW or F344 rats. 
Recipients of 21-4L or nontransgenic F344 BM cells re- 
covered completely from the effects of irradiation and remained 
healthy during an observation period of 6-77 wk after transfer 
(Tables 2 and 3, groups 2G and 3G, Figs.  1 B and 2 C). In 
contrast, all 21 LEW recipients of 21-4H BM cells and all 
42 F344 recipients of t>0.5  x  10  s 33-3 BM cells developed 
persistent  diarrhea  and/or  skin changes within  2-29  wk 
(groups 2D and 3C, median of 4 and 6 wk, respectively). 
Arthritis occurred in a total of seven animals,  six of them 
LEW.  Fatal cachexia was common in the LEW recipients 
(8 of 17 within 4 mo), but occurred in only one of the F344 
recipients.  Histologic lesions similar to those of the sponta- 
neous disease and of the 21-4L recipients of 21-4H BM were 
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Figure 3.  Cell  surface expression  of HLA-B27  on  PBM  in  21-4L 
recipients of BM cells (mAb B1.23.2). (A) B27 expression in a 25-wk-old 
male of the disease-prone 21-4H line (solid trace),  and control mAb (dashed 
trace),  showing pattern previously described (3). (B) B27 expression in a 
16-wk-old 21-4L male, as previously described (3). (C) 21-4L male recip- 
ient of 21-4H BM cells, 27 wk after transfer, with inflammatory disease, 
showing a population with enhanced surface expression of B27 that is 
characteristic of the 21-4H line. (D) Surface expression of B27 in a 21-4L 
male recipient of 21-4H BM cells  that remained healthy, 24 wk after transfer, 
showing a 21-4L host  pattern. 
1610  Bone Marrow  Transfer of HLA-B27-associated Disease in Rats Table  2.  Passive Transfer of B27-associated Disease to Irradiated Nontransgenic (Ntg) LEW Rats 
Cells  injected  With  Skin  Death  Wk of onset  Severity  index 
Group  Donor cells  x l0 -s (range)  Total  disease  Diarrhea  Arthritis  lesions  (1-4 too)  Mean  +  SEM  Mean  •  SEM 
Sublethal  irradiation  (750  tad) 
A  21-4H BM  1  10  9  6  4  5  0  10  •  3  1.4  _+ 0.2 
B  21-4H SP  1.5-3  7  3  1  1  1  0  13  _+  5  0.7  _+  0.2 
C  21-4H LN  2.5-4  7  4  0  0  4  0  21  _+  1  1.1  _+  0.2 
Lethal irradiation  (950-1,050 rad) 
D  21-4H BM  1-3  21  21  20  6  20  8  4_+ 1  2.9  +  0.2 
E  21-4H FL  0.08  _+  0.3  14  14  13  3  7  1  10  +  1  1  _+  0.1 
F  21-4H SP  1  4  3  3  0  3  0  14  +  1  1  +  0.3 
G  21-4L BM  1.5-2  18  0  0  0  0  0  -  - 
H  Ntg LEW FL  0.03-0.3  18  0  0  0  0  0  -  - 
7-11-wk-old Ntg LEW irradiated recipients received i.v. BM, SP, LN, or FL cells from transgenic donor rats of the disease-prone 21-4H line, from 
transgenic donor rats of the disease-resistant 21-4L line, or from Ntg LEW donor rats, and were monitored as described in Table 1. 
arthritic joints (Fig. 2 D). On flow cytometry, BM cells from 
recipients of transgenic BM were predominantly B27 + (Fig. 
4, A-C). Spleen, LN, and PBMC showed surface expression 
of B27 in all subpopulations of lymphoid cells examined, in- 
cluding cells displaying TCR-ot/B, CD4, CD8, CD5, NKP- 
Pl, and the B cell-specific epitope of CD45 (Fig. 5 and data 
not shown). A consistent finding was the presence of a popu- 
lation  of donor-derived  non-T  cells  that  were  B27bns h', 
CD4  dim in the recipients  that developed disease  (Fig.  5, A 
and B). The proportion of these cells, which display monocyte- 
macrophage morphology and stain with the mAb OX-42, 
increased with  disease progression (data  not  shown).  This 
was correlated with absolute monocytosis evident on blood 
smears of sick recipients, and also present in spontaneous dis- 
ease (our unpublished observations). Immunohistochemistry 
of colonic lesions from nontransgenic recipients of BM cells 
from  either  33-3  or  21-4H  donors  showed  that  the  cells 
infiltrating  the  lamina  propria  were  predominantly  B27 § 
(data not shown), suggesting a direct role for donor-derived 
cells  in  the  inflammatory lesions. 
In comparison with the lethally irradiated LEW recipients 
of 21-4H BM cells,  sublethally irradiated recipients showed 
disease of later onset and lesser severity (group 2A), similar 
to the patter seen with 21-4L recipients (group 1A). In addi- 
Table  3.  Passive Transfer of B27-associated Disease to Nontransgenic (Ntg) F344 Irradiated Rats 
Cells  injected  With  Skin  Death  Wk of onset  Severity  index 
Group  Donor cells  x l0 -s (range)  Total  disease  Diarrhea  Arthritis  lesions  (1-4 mo)  Mean  +  SEM  Mean  +  SEM 
Sublethal  irradiation  (750  rad) 
A  33-3  BM  1  12  3  3  0  0  0  35  _+  1.6  ND 
B  33-3  SP or LN  1-1.5  12  0  0  0  0  0  -  - 
Lethal irradiation  (1,050-1,350  rads) 
C  33-3  BM  0.5-3  42  42  42  1  18  1  6  _+  1  1.5  _+  0.1" 
D  33-3 BM  0.12-0.25  6  4  4  0  3  0  13  _+  5  1  •  0.1' 
E  33-3  SP  1  4  2  2  0  2  0  8,  13  ND 
F  33-3  LNS  1  5  0  0  0  0  0  -  - 
G  Ntg F344 BM  0.85  _+  1.5  20  0  0  0  0  0  -  - 
7-12-wk-old Ntg F344 irradiated recipients received i.v. BM, SP, or LN cells from HLA-B27 transgenic donor rats of the disease-prone 33-3 line 
or from Ntg F344 donor rats and were monitored as described in Table 1. 
" Mean _+ SEM of 39 of 42 disease-affected recipients. 
t Mean +  SEM of three of four disease-affected recipients. 
S Recipients in Group F were rescued with  3  x  107 d 16 Ntg F344 FL cells injected along with 33-3 LN cells. 











F  G  H 
f: 
10  o  101  10  2  10 3  10  4  10  0  101  10  2  10  3  10 4  10 0  101  10  2  10 3  10  4  10  0  101  10 2  10  3  10  4 
Fluorescence Intensity 
and 34 wk after transfer, respectively; and (G) lethally irradiated (1,050 tad) nontransgenic LEW male recipient 
Figure 4.  Cell  surface  expression 
of  HLA-B27 on  BM  cells  in 
recipients of BM or FL cells. Single 
color histograms are shown after 
gating to exclude erythrocytes. The 
majority of BM cells express HLA- 
B27 on the surface in the following 
disease-affected  recipients:  (A) 
lethally irradiated (1,050 tad) non- 
transgenic LEW female  recipient of 
21-4H BM cells (group 2D), 6 wk 
after transfer; (B) lethally irradiated 
(1,050 rad) nontransgenic F344 fe- 
male recipient of 33-3 BM  cells 
(group 3C), 31 wk after transfer; 
(D, solid trace) sublethally  irradiated 
(750 tad) nontransgenic LEW male 
recipient of 21-4H BM cells (group 
1A), 56 wk after transfer; (E, solid 
trace) sublethally  irradiated (750 tad) 
nontransgenic LEW female recip- 
ient (group 2B), and (F, solid trace) 
lethally irradiated (1,050 tad) non- 
transgenic  LEW  male  recipient 
(group 2F) of 21-4H spleen cells, 18 
of d15 21-4H FL cells (group 2E), 
34 wk after transfer. Similar engraftment by B27 + BM cells is present (C) in healthy lethally irradiated (1,050 tad) nontransgenic LEW male recipient 
of 21-4L BM cells (group 2G), 59 wk after transfer. In contrast, the proportion of BM cells expressing B27 is much lower or negligible in the following 
healthy recipients; (D, dashed trace) sublethally irradiated (750 rad) nontransgenic LEW female recipient of 21-4H BM cells (group 2A), 24 wk after 
transfer; (E, dashed trace) sublethally irradiated (750 rad) nontransgenic LEW female recipient (group 2B) and (F, dashed trace) lethally irradiated (1,050 
rad) nontransgenic LEW male recipient of 21-4H spleen cells (group 2F), 18 and 34 wk after transfer, respectively; (H, solid trace) lethally irradiated 
(950 rad) 33-3 female recipient of nontransgenic F344 BM cells. Background fluorescence with an irrelevant antibody is shown in F, broken trace, 
and H, dashed trace. 
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Figure  5.  Cell surface expression of HLA-B27 on CD4 + PBMC in 
recipients of BM or spleen cells. (.4) Disease-affected  lethally irradiated 
(1,050 rad) nontransgenic LEW male recipient of 21-4H BM cells (group 
2D), 20 wk after transfer. (B) Disease-affected  lethally irradiated (1,050 
red) nontransgenic F344 male recipient of 33-3 BM cells (group 3C), 13 
wk after transfer. (C) Disease-affected  lethally irradiated (1,050 red) non- 
transgenic LEW male recipient of 21-4H spleen cells (group 2F), 34 wk 
after transfer (same rat as in Fig. 4 F, solid trace). (D) Healthy, lethally 
irradiated (1,050 tad) nontransgenic LEW male recipient of 21-4H spleen 
cells (group 2F), 34 wk after transfer (same rat as in Fig. 4 F, dashed trace). 
Dot plots were obtained for cells with mononuclear morphology, as defined 
by light scatter. Quadrants were defined  by background staining with control 
tion,  recipients with mild or absent  disease manifestations 
showed  a  low  proportion  of B27 +  PBM  and  BM  cells, 
which  indicated  poor engraftment  of donor  marrow  (Fig. 
4 D). Furthermore,  none of the sublethally irradiated F344 
recipients of 33-3 BM developed disease during 6 mo of ob- 
servation (group 3A).  In this strain,  which is characterized 
by  lower  radiosensitivity  than  the  LEW  strain  (data  not 
shown),  none of the 6 F344 recipients that had been irradi- 
ated at 300 tad,  and only 7  of 12 recipients  that  had been 
irradiated at 750 tad,  showed any B27 + PBM.  The propor- 
tion of donor  cells in these engrafted recipients  was lower 
than in the comparably irradiated group of LEW recipients 
of21-4H BM (16  +_  12% vs 44  +  14%). Three of the posi- 
tively engrafted recipients developed chronic diarrhea begin- 
ning  more than  8  mo after transfer. 
TransJer of Spleen and LN  Cells to Nontransgenic  Recipients. 
To further examine the need for stem cell engraftment in the 
transfer of disease, 21-4H and 33-3 spleen and LN cells were 
also transferred  into  sublethally  or lethally  irradiated  non- 
transgenic  recipients.  None  of  the  sublethally  irradiated 
recipients  of 33-3 cells developed any disease manifestation 
mAb. The numbers in each quadrant are the percentage of total cells rep- 
resented by that quadrant. Numbers in parenthesis refer to the CD4  dim 
population displaying morphology and surface markers characteristic of 
monocytes. 
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sublethally irradiated recipients of 21-4H cells developed di- 
arrhea, with typical histological lesions of  enterocohtis (groups 
2B and C). 5 of these 14 recipients also developed alopecia 
14-22 wk after transfer with histological lesions restricted 
to perifoUiculitis, as previously seen in similarly irradiated 
21-4L recipients. The recipients in these groups showed poor 
engraftment of the transgenic  marrow ceils except for the 
one of spleen cells that developed chronic diarrhea (Fig. 4, 
E and F). Nonetheless,  between 3 and 22% of T lympho- 
cytes in peripheral blood or LN were of donor origin when 
examined 11-45 wk after transfer, indicating that the donor 
lymphocytes were not completely rejected. After lethal ir- 
radiation,  three of four recipients of 21-4H spleen ceils and 
two of four recipients of 33-3 spleen cells developed disease 
that was milder overall than that seen after BM transfer (groups 
2F and 3E). None of five recipients of 33-3 LN cells devel- 
oped any disease  manifestation  up to 19 wk after transfer (group 
3F). In all these groups,  the transfer of disease consistently 
correlated with BM engraftment (Fig. 4 F) and with the pres- 
ence  of B27bag  ht,  CD4  aim  monocytic cells in  peripheral 
blood, whereas in the recipients that remained healthy, the 
CD4  d~ cells were host derived (compare C and D in Fig. 5). 
Transfer of  Disease with FL Cells.  The correlation between 
the degree of BM engraftment and efficiency  of transfer sug- 
gested a necessary role played by BM-derived hematopoietic 
precursors for which mature cells from peripheral lymphoid 
organs could not readily substitute.  To test this hypothesis, 
FL cells were used as a source of precursor cells to reconsti- 
tute lethally irradiated nontransgenic LEW recipients. FL cells 
from day 21 and day 15 21-4H fetuses were used in two con- 
secutive experiments. Transfer of disease was observed in all 
14 recipients of transgenic FL cells (group 2E, Fig. 1 C), al- 
though the delay to disease onset was longer than following 
21-4H BM cell transfer. None of the 18 recipients of non- 
transgenic FL cells (nine from the nontransgenic littermates 
of the 21-4H transgenic donors and nine from LEW donors) 
developed any disease  manifestations (group 2H). Similar dis- 
ease also occurred in five of seven F344 recipients of day 16 
FL cells from 33-3 donors by 4 mo after transfer. Flow cytom- 
etry indicated the same pattern of BM engraftment (Fig. 4 
G) and presence of B27bns  ht, CDM  im monocytic cells (data 
not shown) in the recipients of FL cells as was seen in the 
recipients of BM or spleen cells that developed disease. 
Nontransgenic BM Ameliorates Disease in 33-3 Recipients. 
The foregoing results suggested that BM-derived precursor 
cells with the capacity to develop into cells with high expres- 
sion of HLA-B27 are necessary for disease development in 
otherwise normal rats. If this were so, it might be expected 
that the spontaneous disease would be ameliorated by recon- 
stitution with nontransgenic BM. To test this prediction, we 
treated 10 33-3 rats that had advanced disease  with lethal irra- 
diation (950 rad) followed by reconstitution with either non- 
transgenic  BM or 33-3 BM (Fig. 6). All five recipients of 
33-3 BM developed an exacerbation of diarrhea and skin le- 
sions within a few weeks of transfer and died within 14 wk. 
In contrast, the five recipients of nontransgenic BM showed 
prompt improvement. Skin lesions and diarrhea disappeared 
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Figure  6.  Treatment of the spontaneous disease in I-tLA-B27 transgenic 
rats by transplantation  of nontransgenic  BM. Recipients for transfer were 
rats of the 33-3 line with advanced disease. After lethal irradiation  (950 
tad),  rats were given either 33-3 BM (closed circles) or nontransgenic  BM 
(open circles). Clinical score represents the average daily score for each week 
after transfer. Data represent  the mean  _+  SEM of five animals for each 
group,  except weeks  11 and  12 for the group receiving 33-3 BM (four 
and three rats,  respectively). 
completely  in all five recipients after 8 wk. Two of these later 
developed  an unexplained cachexia  that was fatal 14 and 18 wk 
after transfer, but the remaining three all survived at least 
9 mo after transfer free of clinical disease. Flow cytometry 
showed almost complete absence of B27 + cells in the BM 
(Fig. 4/-/), blood, and peripheral lymphoid organs (data not 
shown). Histological  examination  of the gut showed only 
mild evidence of inflammation and scarring of the colon in 
the group reconstituted with nontransgenic BM (Fig. 1 D), 
whereas the group receiving 33-3 BM showed typical severe 
lesions (data not shown). One of the two rats replaced with 
normal F344 BM that died spontaneously  showed hepatic 
abnormalities consisting  of fatty degeneration with a non- 
specific granulomatoid reaction, probably secondary to infec- 
tion. The liver of the other rat was normal except for rare, 
mild periductal mononuclear  cell infiltration that is also occa- 
sionally seen in the spontaneous disease (data not shown). 
Discussion 
Disease Transfer and the Requirement for Bone Marrow En- 
graftment.  Gut, skin, and joint disease in the recipients was 
induced by transfer of BM cells from the disease-prone 21- 
4H and 33-3 lines but not from the disease-resistant 21-4L 
line or from nontransgenic donors.  In view of the correla- 
tion between disease susceptibility and high levels of B27 ex- 
pression (3), this suggests strongly that the disease suscepti- 
bility of the 21-4H  and  33-3 lines  can  be  attributed  to 
expression of high levels of B27 in one or more populations 
of BM-derived cells. Although the results with whole BM 
cells did not exclude the possibility that transfer of disease 
required cotransfer of mature effector cells (14), subsequent 
experiments indicated that irradiated nontransgenic recipients 
of T cell--depleted  BM (our unpublished findings) or FL cells 
from donors of disease-prone lines also developed inflamma- tory disease similar to that occurring spontaneously in the 
donor lines. It thus appears that hematopoietic precursor cells 
from premorbid rats of the disease-prone lines are sufficient 
to confer disease susceptibility in an otherwise nontransgenic 
environment. 
In contrast to these results with BM and FL cell transfer, 
comparable numbers of spleen or LN cells injected into simi- 
larly irradiated recipients either induced less severe pathologic 
manifestations, almost exclusively limited to late perifollicu- 
litis in the case of sublethally irradiated recipients, or had 
no  pathological  effect.  These  observations  predicted  that 
transfer of disease, particularly gut and joint disease, requires 
engraftment of BM stem cells in the recipients, and this predic- 
tion was supported by immunofluorescence analysis of BM 
and peripheral lymphoid cells from the various recipients.  Be- 
cause spleen or LN cells in the absence of BM engraftment 
failed to transfer disease, the findings further suggest a neces- 
sary role played by BM-derived hematopoietic precursors for 
which cells from peripheral lymphoid organs such as mature 
lymphocytes cannot readily substitute. Because of their high 
levels of expression of HLA-B27 in the disease-prone trans- 
genic lines and also because of their involvement in MHC- 
dependent immune responses, BM-derived APC  from the 
monocytic or dendritic cell lineages are likely to play such 
a role. Evidence for this idea was provided by the observation 
that the incidence and progression of disease in the recipients 
correlated with the accumulation of a donor-derived mono- 
cytic population. Recovery from disease observed in 33-3 rats 
after replacement with  nontransgenic BM may have been 
linked to this same population of precursor cells, although 
this was not formally demonstrated. Although it is conceiv- 
able  that  donor cells  were rejected by the nontransgenic 
recipients in proportion  to the level of expression of B27, 
such that spleen or LN cells showed less efficiency in trans- 
ferring disease than the more immature cells provided by BM 
or FL cells, this was unlikely to happen in the 21-4L recipients, 
and the long-term persistence of mature B27 donor lympho- 
cytes  regularly  observed  in  the  blood  of  nontransgenic 
recipients of 21-4H or 33-3  LN or spleen cells also argues 
against this possibility. 
Although a BM-derived nonlymphocyte population  ap- 
pears  to be necessary for disease transfer, it is likely that T 
lymphocytes are also essential to the disease pathogenesis, since 
athymic nude rats bearing the 33-3  transgene locus fail to 
develop inflammatory  disease unless reconstituted with T cells, 
even though BM cells from these nude rats can transfer dis- 
ease to irradiated F344 recipients (our unpublished results). 
Differences between the  Spontaneous and  Transferred Dis- 
ease.  The transferred disease bore dose clinical and histo- 
logic resemblance to the spontaneous disease, but with some 
differences. The most striking of these was the absence in 
the transfer recipients of male genital inflammation, which 
is a prominent part of the spontaneous disease. This finding 
suggests that the inflammatory genital disease is dependent 
upon a radiosensitive tissue,  most likely sperm, which were 
uniformly absent from recipient testis and epididymis. Ar- 
thritis was less frequent in the transfer recipients than would 
have been predicted from the spontaneous disease,  particu- 
larly in the recipients of 33-3 cells. The reason for this is un- 
clear, but may be related to an effect of irradiation, since ar- 
thritis disappeared after irradiation in the 33-3 recipients of 
33-3 BM and did not return. Finally, skin lesions in the transfer 
recipients tended to  occur earlier in relation to  the other 
findings than was the case in the spontaneous disease. 
Differences between the Transferred  Disease and GVHI~  Like 
B27-associated disease, GVHD in the rat can cause inflam- 
matory lesions of the gut,  skin, and joints (15-17).  It was 
therefore of concern, especially after genetic contamination 
of the 21-4H line was identified, that BM cells from these 
donors might have actually induced a form of GVHD that 
we took for passively transferred B27-associated disease. This 
seems unlikely for several reasons. First, the clinical and histo- 
logic appearance and the time course of both the spontaneous 
and passively  transferred disease in the B27 rats differ sub- 
stantially from that  described for either acute or chronic 
GVHD in the rat. For example, the prominent hepatic and 
salivary gland abnormalities, vasculitis and pulmonary fibrosis 
of GVHD, are not found in the B27-associated  disease. Co- 
lonic lesions are lacking in chronic GVHD in the rat but 
are a consistent and prominent feature of B27-associated  dis- 
ease; and the scleroderma-like skin changes of chronic GVHD 
are not found in the B27-associated disease, the B27-associated 
skin lesions being instead hyperplastic. Second, reproducible 
disease transfer was obtained with both 21-4H and 33-3 donors, 
the latter of which showed no evidence of genetic contami- 
nation. Third, the nontransgenic parents of the 21-4H donors 
in later transfers were all authentic LEW males, and hence 
there was no immunologic basis for GVHD in the nontrans- 
genic LEW recipients of cells from these donors. Fourth, LN 
cells, which are usually potent inducers of GVHD (18), were 
much less efficient in inducing disease manifestations than 
cells lacking mature T lymphocytes such as FL cells. Fifth, 
disease transfer with FL cells segregated perfectly with the 
B27 status of the 21-4H fetal donors (groups 2E and H), and 
independently of variations in genetic background (our un- 
published observations).  Therefore, despite the potential com- 
plication presented by the genetic contamination of the LEW 
lines,  the data strongly suggest that the transferred disease 
is a B27  transgene-associated phenomenon, irrespective of 
the genetic background. 
Comparisons with other Disease Transfer Models.  The pas- 
sive transfer of disease in the B27 transgenic rats bears similarity 
to studies of the BB/W rat and NOD mouse models of MHC- 
linked insulin-dependent diabetes mellitus, in which transfer 
of disease with BM cells (19-21),  participation of T cells in 
disease pathogenesis (22, 23), and a lack of requirement for 
genetic  abnormality  in  the  target  tissue  (20)  have  been 
identified. BM cells have also been implicated in the transfer 
or treatment of other autoimmune disease in humans and 
in animal models (24, 25), and in the efficient transfer of the 
delayed hypersensitivity response in rats (26).  Although T 
effector cells are known to participate in these processes, ad- 
ditional marrow-derived elements such as APC (27), also are 
thought to be involved. 
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tionship to Human Disease.  The disease of the B27 transgenic 
rats bears a striking association to B27-associated  disease in 
humans, the pathogenesis of which is still poorly understood. 
A variety of mechanisms have been proposed, largdy based 
on the well documented triggering role of infectious agents 
in B27-associated  reactive arthritis. These include molecular 
mimicry (28, 29), peptide binding (30), and altered bacterial 
handling (31, 32). Most hypotheses have depended upon the 
principle that class I MHC molecules are expressed in most 
somatic tissues (33). Since it is clear from the results presented 
here that B27 need not be expressed in nonmarrow-derived 
elements in the thymus, or in sites of disease such as intes- 
tinal mucosa, synovium, or skin in order for B27-mediated 
disease in rats to be induced in these sites, these results should 
help exclude consideration of hypotheses that would depend 
upon B27 expression in non-BM-derived tissues.  However, 
the specific disease mechanism remains a matter of specula- 
tion. BM-derived APC expressing B27 at the high levels seen 
in the disease-susceptible  lines could potentially modify im- 
mune regulation in the thymus, where BM-derived cells par- 
ticipate in negative and perhaps positive selection of maturing 
thymocytes (34,  35) and/or in peripheral lymphoid tissue, 
where presentation of antigen above a critical level or in a 
nonphysiologic manner (36) may trigger an immunopatho- 
logic process.  B27  transgenic rats can mount strong B27- 
restricted CTL responses (37), but it is not yet known whether 
this is the predominant effector mechanism in either the spon- 
taneous or transferred disease. Presentation of a B27-derived 
peptide (38, 39) by rat MHC molecules is another potential 
disease mechanism that has not yet been excluded. Further 
experiments should help identify the role ofT cells, the specific 
BM-derived populations responsible for the transferred dis- 
ease, and the molecular role of B27, as well as whether rec- 
ognition of an exogenous antigen (31) or a self-antigen (40) 
is involved. The transfer model described here will be an es- 
sential element in these experiments. 
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